ADA Bridging Assay for Exposed C-Terminal Antibody Interference

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for detecting treatment-emergent anti-drug antibodies (ADA's) are hindered by pre-existing antibodies that bind to the exposed C-terminal regions of immunoglobulin variable domains, leading to interference and inaccurate measurements.

Innovation Solution

An ADA assay is developed that can measure true treatment-emergent ADA's by modifying a bridging assay format to account for interfering factors, specifically designed for proteins with exposed C-terminal regions, such as VH domains or VHH domains, using techniques like electrochemiluminescence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If a standard bridging assay is used to detect anti-drug antibodies, then the assay can detect antibodies against the drug, but pre-existing antibodies bind to the exposed C-terminal regions and cause interference leading to inaccurate measurements

Engineering Contradiction:

Improveaccuracy of ADA measurementVSAvoidinterference from pre-existing antibodies

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent removes the interfering exposed C-terminal region from the drug molecule by proteolytic cleavage, specifically cutting at the Arg-Gly bond in the Fc region. This extraction of the problematic C-terminal region eliminates the binding site for pre-existing interfering antibodies, allowing accurate detection of true treatment-emergent ADA without interference.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The assay performs a preliminary proteolytic cleavage step before the antibody detection step. By pre-treating the drug with protease to remove the C-terminal region, the assay eliminates interference before the measurement process begins, ensuring that subsequent antibody binding reflects true ADA levels rather than pre-existing antibodies.

Inventive Principle:

Principle #10Preliminary action

2Adaptability or versatility

If the assay targets the exposed C-terminal region of immunoglobulin variable domains, then it can detect antibodies against drugs with this structural feature, but pre-existing antibodies present in the sample interfere with the measurement

Engineering Contradiction:

Improveapplicability to drugs with exposed C-terminal regionsVSAvoidreliability of ADA detection

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent extracts and removes the exposed C-terminal region that serves as the binding epitope for pre-existing interfering antibodies. By cleaving the drug at the Arg-Gly bond to remove this specific region, the assay maintains versatility for detecting ADA against drugs with exposed C-terminals while eliminating the reliability issue caused by interfering antibodies binding to this same region.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The assay performs preliminary proteolytic processing of the drug to remove the problematic C-terminal region before exposure to the sample. This preliminary action ensures that when the processed drug is then used in the assay, it cannot bind pre-existing interfering antibodies, thereby maintaining both adaptability to various drug structures and reliability of measurements.

Inventive Principle:

Principle #10Preliminary action

3Manufacturing precision

If the assay uses the native drug structure with exposed C-terminal regions, then it reflects the actual drug form administered, but pre-existing antibodies cause false positive or inaccurate ADA measurements

Engineering Contradiction:

Improvefidelity to original drug structureVSAvoidaccuracy of treatment-emergent ADA detection

Core Design Contradiction:

Manufacturing precisionVSMeasurement precision

Solution Approach 1:

The patent selectively extracts only the interfering C-terminal region while preserving the rest of the drug's antigenic structure. By removing specifically the Arg-Gly-containing C-terminal portion that binds pre-existing antibodies, the assay maintains fidelity to the original drug's immunogenic regions while eliminating measurement interference, thus achieving both structural fidelity and measurement accuracy.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The assay performs preliminary selective proteolytic modification of the drug structure before the detection step. This preliminary action modifies only the problematic C-terminal region while leaving the rest of the drug structure intact, ensuring that the modified drug still represents the original drug's antigenic properties for accurate ADA detection without pre-existing antibody interference.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The assay effectively distinguishes and measures treatment-emergent ADA's in the presence of pre-existing antibodies, enhancing the reliability and accuracy of ADA detection.

Implementation Method 1

using techniques like electrochemiluminescence

Methodology Applied

Scientific EffectElectrochemiluminescence: Electrochemiluminescence

Data Source

PatentUS12553901B2Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies

Publication Date: 2026.02.17 ABLYNX NV

AI summary

Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.